Search results for "MT"

showing 10 items of 2759 documents

Narratives of Patients with Fatal Outcomes During the Phase 2 TITAN and Phase 3 HERCULES Studies

2019

Background: Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare but life-threatening thrombotic microangiopathy, with an untreated mortality rate of >90%. Prompt treatment with therapeutic plasma exchange (TPE) and immunosuppression improves outcomes in patients with aTTP, but 10-20% of patients still die acutely from this disease. The aim of this analysis was to describe in more detail the characteristics and disease courses of the patients who died during the caplacizumab clinical development program. Methods: Patient narratives on all deaths occurring during the phase 2 TITAN and phase 3 HERCULES studies were extracted. Results: In the overall study periods, a total of 6 pat…

medicine.medical_specialtyStudy drugbusiness.operationbusiness.industryRecurrent episodeImmunologyCell BiologyHematologyOctapharmaPlaceboBiochemistryAdamts13 activityFamily medicinemedicineRisk of mortalityDisease characteristicsIn patientbusinessBlood
researchProduct

Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study.

2020

BACKGROUND Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life-threatening autoimmune thrombotic microangiopathy. Caplacizumab, an anti-von Willebrand Factor Nanobody® , is effective for treating aTTP episodes and is well tolerated. OBJECTIVES AND METHODS In the phase 3 HERCULES trial (NCT02553317), patients with aTTP received double-blind caplacizumab or placebo during daily therapeutic plasma exchange (TPE) and for ≥30 days thereafter. Patients who experienced an exacerbation while on blinded study drug treatment switched to receive open-label caplacizumab plus re-initiation of daily TPE. Exacerbations were defined as recurrence of disease occurring within 30 days after ce…

medicine.medical_specialtyThrombotic microangiopathyExacerbation610 Medicine & health030204 cardiovascular system & hematologyvon Willebrand factorPlacebocaplacizumabthrombotic thrombocytopenic03 medical and health sciences0302 clinical medicineVon Willebrand factorFibrinolytic AgentsInternal medicineMedicineHumansPlatelet610 Medicine & healthAdverse effectADAMTS13 proteinAcquired Thrombotic Thrombocytopenic PurpurabiologyPlasma ExchangePurpura Thrombotic Thrombocytopenicbusiness.industryBrief ReportHematologySingle-Domain Antibodiesmedicine.diseaseTHROMBOSISpurpurabiology.proteinCaplacizumabbusinessJournal of thrombosis and haemostasis : JTH
researchProduct

Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management

2021

Thrombotic thrombocytopenic purpura (TTP) is a rare thrombotic microangiopathy characterized by microangiopathic hemolytic anemia, severe thrombocytopenia, and ischemic end organ injury due to microvascular platelet-rich thrombi. TTP results from a severe deficiency of the specific von Willebrand factor (VWF)-cleaving protease, ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13). ADAMTS13 deficiency is most commonly acquired due to anti-ADAMTS13 autoantibodies. It can also be inherited in the congenital form as a result of biallelic mutations in the ADAMTS13 gene. In adults, the condition is most often immune-mediated (iTTP) whereas congenital TTP (cTT…

medicine.medical_specialtyThrombotic microangiopathyTTPdiagnosisThrombotic thrombocytopenic purpuralcsh:MedicineReview030204 cardiovascular system & hematologycaplacizumabGastroenterology03 medical and health sciences0302 clinical medicineVon Willebrand factorhemic and lymphatic diseasesInternal medicinefollow-upmedicinethrombotic thrombocytopenic purpuratreatmentbiologybusiness.industrylcsh:RGeneral MedicineMicroangiopathic hemolytic anemiamedicine.diseaseADAMTS13ADAMTS13biology.proteinRituximabFresh frozen plasmaCaplacizumabbusiness030215 immunologymedicine.drugJournal of Clinical Medicine
researchProduct

Algoritmo diagnóstico-terapéutico de las microangiopatías trombóticas. A propósito de 2 casos

2022

Thrombotic microangiopathies (TMA) are a group of clinical syndromes associated with haemolytic anaemia, thrombocytopenia and organ dysfunction, mainly renal or neurological. They are associated with significant morbidity and mortality, so early diagnosis and treatment are essential. In this article we report two cases of TMA; a patient with thrombotic thrombocytopenic purpura (TTP) and a patient with atypical haemolytic uraemic syndrome (aHUS).

medicine.medical_specialtyThrombotic microangiopathyTherapeutic algorithmThrombotic thrombocytopenic purpura030204 cardiovascular system & hematologyurologic and male genital diseasesCritical Care and Intensive Care MedicineGastroenterology03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesInternal medicinemedicineThrombotic Microangiopathiesneoplasmsbusiness.industryOrgan dysfunction030208 emergency & critical care medicineEculizumabmedicine.diseaseADAMTS13Anesthesiology and Pain MedicineHaemolytic-uraemic syndromemedicine.symptombusinessmedicine.drugRevista Española de Anestesiología y Reanimación
researchProduct

No Evidence for Classic Thrombotic Microangiopathy in COVID-19

2021

Background: Coronavirus disease-2019 (COVID-19) triggers systemic infection with involvement of the respiratory tract. There are some patients developing haemostatic abnormalities during their infection with a considerably increased risk of death. Materials and Methods: Patients (n = 85) with SARS-CoV-2 infection attending the University Medical Center, Mainz, from 3 March to 15 May 2020 were retrospectively included in this study. Data regarding demography, clinical features, treatment and laboratory parameters were analyzed. Twenty patients were excluded for assessment of disseminated intravascular coagulation (DIC) and thrombotic microangiopathy (TMA) due to lack of laboratory data. Resu…

medicine.medical_specialtyThrombotic microangiopathymicroangiopathylcsh:Medicine030204 cardiovascular system & hematologyFibrinogenGastroenterologyArticleProcalcitonin03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesInternal medicineMedicinePlateletdisseminated intravascular coagulationDisseminated intravascular coagulationbusiness.industrylcsh:RMicroangiopathyCOVID-19General Medicinemedicine.diseaseADAMTS13ADAMTS13Blood pressurecoronavirus disease030220 oncology & carcinogenesisbusinessmedicine.drugJournal of Clinical Medicine
researchProduct

Control of ovarian steroidogenesis by insulin-like peptides in the blowfly (Phormia regina).

2004

0022–0795/04/0181–147; This study investigated the ability of insulin and of insect insulin-like peptides (ILPs) to stimulate ovarian steroidogenesis in the blowfly Phormia regina. Bovine insulin was active on ovaries isolated in vitro, which showed an age-dependent sensitivity; this peptide progressively stimulated steroidogenesis in ovaries isolated from the third day after adult molt, but not in younger ones, and had maximal activity after the fifth day. This stimulatory effect was observed equally from females reared in the presence or in the absence of males, excluding a regulatory effect of mating. The mode of action of insulin in blowflies did not involve cAMP, but triggered a specif…

medicine.medical_specialtyTime FactorsEndocrinology Diabetes and Metabolismmedicine.medical_treatmentMorpholinesEndogenyblowflychemistry.chemical_compoundPhosphatidylinositol 3-KinasesEndocrinologyOrgan Culture TechniquesInternal medicineControlmedicineAnimalsInsulinPhosphatidylinositolPI3K/AKT/mTOR pathwayPhosphoinositide-3 Kinase InhibitorsbiologyInsulinDipteraNeuropeptidesOvaryEstrogensPhormia reginabiology.organism_classificationinsulin-like peptidesIn vitroStimulation ChemicalInsulin receptorEndocrinologychemistryChromonesPhormia reginaInsect Hormonesbiology.proteinCattleFemaleovarian steroidogenesisSignal transductionThe Journal of endocrinology
researchProduct

Insulin resistance aggravates atherosclerosis by reducing vascular smooth muscle cell survival and increasing CX3CL1/CX3CR1 axis.

2014

Aims Insulin resistance (IR) is a major risk factor for cardiovascular disease and atherosclerosis. Life-threatening acute events are mainly due to rupture of unstable plaques, and the role of vascular smooth muscle cells (VSMCs) in this process in IR, Type 2 diabetes mellitus, and metabolic syndrome (T2DM/MetS) has not been fully addressed. Therefore, the role of VSMC survival in the generation of unstable plaques in T2DM/MetS and the involvement of inflammatory mediators was investigated. Methods and results Defective insulin receptor substrate 2 (IRS2)-mediated signalling produced insulin-resistant VSMCs with reduced survival, migration, and higher apoptosis than control cells. Silencing…

medicine.medical_specialtyVascular smooth musclePhysiologyCell Survivalmedicine.medical_treatmentMyocytes Smooth MuscleCX3C Chemokine Receptor 1InflammationMice TransgenicBiologyMuscle Smooth VascularInsulin resistanceApolipoproteins EPhysiology (medical)Internal medicinemedicineAnimalsHumansProtein kinase BPI3K/AKT/mTOR pathwayCells CulturedMice KnockoutChemokine CX3CL1Insulinmedicine.diseaseAtherosclerosisIRS2Mice Inbred C57BLAtheromaEndocrinologyDiabetes Mellitus Type 2cardiovascular systemReceptors Chemokinemedicine.symptomInsulin ResistanceCardiology and Cardiovascular MedicineSignal TransductionCardiovascular research
researchProduct

Femtosecond laser-assisted superficial keratectomy as a treatment for bilateral band keratopathy

2013

medicine.medical_specialtyVisual acuitybusiness.industrymedicine.medical_treatmentGeneral Medicinemedicine.diseaseLaser assistedLaserCurettagelaw.inventionlawOphthalmologyFemtosecondmedicineCombined Modality Therapymedicine.symptombusinessSuperficial keratectomyBand keratopathyArchivos de la Sociedad Española de Oftalmología (English Edition)
researchProduct

Lipid Activates mTORC1 and mTORC2 in the Absorption of Dietary Triglycerides

2018

Mechanistic target of rapamycin (mTOR) senses amino acids; however, its role in lipid metabolism is less established. Organismal lipid requirements are largely met through dietary intake. How nutrient sensing mechanisms in gut interface with dietary fat remains unclear. Here we reveal fundamental and cooperative roles for mTOR complexes 1 and 2 (mTORC1/2) in absorption of dietary triglycerides. Dietary lipid activates mTORC1/2 signaling in gut. Hyperactivating mTORC1 by deleting Tsc1 is sufficient to promote triglyceride absorption and metabolic disease in high fat-fed mice. Conversely, blocking mTORC1/2 by deleting Raptor or Rictor each decreases triglyceride absorption. Loss of Raptor seq…

medicine.medical_specialtybiologyTriglycerideChemistrydigestive oral and skin physiologyHypertriglyceridemiaDietary lipidLipid metabolismmTORC1medicine.diseasemTORC2chemistry.chemical_compoundEndocrinologyInternal medicinemedicinebiology.proteinMechanistic target of rapamycinPI3K/AKT/mTOR pathwaySSRN Electronic Journal
researchProduct

Patterns of changes of anti‐ADAMTS13 after plasma exchange

2006

An enzyme-linked immunosorbent assay (ELISA) has recently been developed to detect antibodies against the von Willebrand factor-cleaving protease ADAMTS13 in patients with thrombotic thrombocytopenic purpura (TTP). The ELISA is based on incubation of plasma with immobilized recombinant ADAMTS13 followed by visualization of IgG and IgM antibodies by means of secondary enzyme-labeled antibodies [1]. In a recent study, anti-ADAMTS13 IgG antibodies were detected in most patients with TTP (97%) characterized by severe ADAMTS13 deficiency (< 10% of normal) [1]. The ELISA was more sensitive than the standard inhibitor assay based upon ADAMTS13 neutralizing activity, which gave positive results in …

medicine.medical_specialtybiologybusiness.industryThrombotic thrombocytopenic purpuraAntibody titerHematologymedicine.diseaseGastroenterologyADAMTS13Immunoglobulin GTiterhemic and lymphatic diseasesInternal medicineImmunologymedicinebiology.proteinPlateletAntibodybusinessIncubationJournal of Thrombosis and Haemostasis
researchProduct